Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy by Patterson, EI et al.
1 
 
Evidence of exposure to SARS-CoV-2 in cats and dogs from households in 1 
Italy 2 
E.I. Patterson1, G. Elia2, A. Grassi3, A. Giordano4, C. Desario2, M. Medardo5, S.L. Smith6, E.R. 3 
Anderson1, T. Prince7, G.T. Patterson6, E. Lorusso2, M.S. Lucente2, G. Lanave2, S. Lauzi4, U. 4 
Bonfanti5, A. Stranieri4, V. Martella2, F. Solari Basano8, V.R. Barrs9, A.D. Radford6, U. 5 
Agrimi10, G. L. Hughes1, S. Paltrinieri4, N. Decaro2* 6 
 7 
1 Departments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical 8 
Disease, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK 9 
2 Department of Veterinary Medicine, University of Bari Aldo Moro, Strada Prov. per 10 
Casamassima Km 3, 70010Valenzano (BA), Italy     11 
3 I-VET srl, Laboratorio di Analisi Veterinarie, Via Ettore Majorana, 10 - 25020 Flero (BS), Italy 12 
4 Department of Veterinary Medicine, University of Milan; Veterinary Teaching Hospital, 13 
University of Milan, Via dell'Università 6, 26900 Lodi, Italy. 14 
5 La Vallonèa Veterinary Diagnostic Laboratory, via G. Sirtori 9, 20017 Passirana di Rho (MI), 15 
Italy 16 
6 Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Leahurst 17 
Campus, Chester High Road, Neston, CH64 7TE, UK 18 
7 NIHR Health Protection Unit in Emerging and Zoonotic Infections, Department of Clinical 19 
Infection, Microbiology and Immunology, University of Liverpool, Liverpool UK. 20 
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (whichthis version posted July 23, 2020. . https://doi.org/10.1101/2020.07.21.214346doi: bioRxiv preprint 
2 
 
8 Arcoblu s.r.l., via Alessandro Milesi 5, 20133 Milan, Italy 21 
9 City University’s Jockey Club College of Veterinary Medicine and Life Sciences, 5/F, Block 22 
1A, To Yuen Building, 31 To Yuen Street, Kowloon, Hong Kong 23 
10 Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di 24 
Sanità, Viale Regina Elena, 299, 00161 Rome, Italy.  25 
*Correspondence to: Nicola Decaro, DVM, PhD, Dipl. ECVM, Department of Veterinary 26 
Medicine, University of Bari, Valenzano, Bari, Italy; tel. 00390804679832; fax 27 
00390804679843; e-mail: nicola.decaro@uniba.it  28 
 29 
Abstract: SARS-CoV-2 originated in animals and is now easily transmitted between people. 30 
Sporadic detection of natural cases in animals alongside successful experimental infections of 31 
pets, such as cats, ferrets and dogs, raises questions about the susceptibility of animals under 32 
natural conditions of pet ownership. Here we report a large-scale study to assess SARS-CoV-2 33 
infection in 817 companion animals living in northern Italy, sampled at a time of frequent human 34 
infection. No animals tested PCR positive. However, 3.4% of dogs and 3.9% of cats had 35 
measurable SARS-CoV-2 neutralizing antibody titers, with dogs from COVID-19 positive 36 
households being significantly more likely to test positive than those from COVID-19 negative 37 
households. Understanding risk factors associated with this and their potential to infect other 38 
species requires urgent investigation. 39 
One Sentence Summary: SARS-CoV-2 antibodies in pets from Italy. 40 
Main Text: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 41 
December 2019 in Wuhan, Hubei province, China (1), possibly as a spillover from bats to 42 
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humans (2), and rapidly spread worldwide becoming a pandemic (3). Although the virus is 43 
believed to spread almost exclusively by human-to-human transmission, there are concerns that 44 
some animal species may contribute to the ongoing SARS-CoV-2 pandemic epidemiology (4). 45 
To date, sporadic cases of SARS-CoV-2 infection have been reported in dogs and cats. These 46 
include detection of SARS-CoV-2 RNA in respiratory and/or fecal specimens of dogs and cats 47 
with or without clinical signs (5-7), as well as of specific antibodies in sera from pets from 48 
coronavirus disease 2019 (COVID-19) affected areas (7,8). In addition, experimental infection of 49 
various animal species has demonstrated that while dogs appear poorly susceptible to SARS-50 
CoV-2 infection, developing asymptomatic infections and shedding low-titer or no virus, cats 51 
develop respiratory pathology and shed high titers of SARS-CoV-2, even being able to infect in-52 
contact animals (9,10). Wide scale testing of susceptible species is needed to assess the extent of 53 
animal infection under more natural conditions of husbandry. Here, we conducted an extensive 54 
epidemiological survey from March to May 2020 in cats and dogs living in Italy, either in 55 
SARS-CoV-2 positive households or living in geographic areas that were severely affected by 56 
COVID-19. To our knowledge, this is the largest study to investigate SARS-CoV-2 in 57 
companion animals to date. 58 
All animals were sampled by their private veterinary surgeon during routine healthcare visits. 59 
Sampling of animals for this study was approved by the Ethics Committee of the Department of 60 
Veterinary Medicine, University of Bari, Italy (approval number 15/2020). A total of 540 dogs 61 
and 277 cats were sampled from different Italian regions, mostly Lombardy (476 dogs, 187 cats). 62 
Animals were sampled either from regions severely affected by COVID-19 outbreaks in humans 63 
or from those that offered convenient access to samples. Oropharyngeal (306 dogs, 175 cats), 64 
nasal (185 dogs, 77 cats), and/or rectal (66 dogs, 30 cats) swabs were collected from the sampled 65 
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pets. For 340 dogs and 188 cats, full signalment and clinical history were available, including 66 
breed, sex, age, exposure to COVID-19 infected humans (COVID-19 positive household, 67 
suspected COVID-19 positive household but not confirmed by specific assay, and COVID-19 68 
negative household), presence of respiratory signs (cough, sneezing, conjunctivitis, nasal and/or 69 
ocular discharge). 70 
Sera were available for 188 dogs and 63 cats for which complete signalment, history and location 71 
were available (Fig. 1). Additional sera were collected from diagnostic laboratories for 200 dogs 72 
and 89 cats from the affected areas, but which lacked further historical information. 73 
Detection of SARS-CoV-2 RNA used two real-time RT-PCR assays targeting nucleoprotein and 74 
envelope protein genes as previously described (11). Plaque reduction neutralization tests 75 
(PRNT) were using a previously established protocol (8) with SARS-CoV-76 
2/human/Liverpool/REMRQ0001/2020 isolate was cultured as previously described (9). 77 
PRNT80 was determined by the highest dilution with  80% reduction in plaques compared to 78 
the control. 79 
All of 839 collected swab samples tested negative for SARS-CoV-2 RNA, including 38 cats and 80 
38 dogs that showed respiratory symptoms at the time of sampling, suggesting absence of active 81 
SARS-CoV-2 infection in the tested animals. In addition, 64 of these dogs and 57 of the cats that 82 
tested negative were living in households previously confirmed as having had COVID-19.  83 
SARS-CoV-2 neutralizing antibodies were detected in 13 dogs (3.35%) and 6 cats (3.95%), with 84 
titers ranging from 1:20 to 1:160 and from 1:40 to 1:1280 in dogs and cats, respectively. Of 85 
samples from households with known COVID-19 status, neutralizing antibodies were detected in 86 
6 of 47 dogs (12.8%) and 1 of 22 cats (4.5%) from COVID-19 positive households, 1 of 7 dogs 87 
(14.3%) and 0 of 3 cats (0%) from suspected COVID-19 positive households and 2 of 133 dogs 88 
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(1.5%) and 1 of 38 cats (2.6%) from COVID-19 negative households (Table 1). For those 423 89 
animals where an age was recorded, 0 of 30 aged less than 1 year (0%), 6 of 92 aged 1-3 years 90 
(6.5%), 3 of 102 aged 4-7 years (2.9%) and 6 of 199 aged 8 and over (3.0%) tested positive. 91 
None of the animals with neutralizing antibodies displayed respiratory symptoms at the time of 92 
sampling.  93 
Reference sera or ascitic fluids from animals previously shown to be positive for canine enteric 94 
coronavirus (14), canine respiratory coronavirus (15) and feline coronavirus (16) tested negative 95 
by the PRNT assay for SARS-CoV-2, confirming the specificity of the obtained results (8).  96 
Dogs were significantly more likely to test positive for SARS-CoV-2 neutralizing antibodies if 97 
they came from a known COVID-19 positive household (Fisher’s exact test, p=0.004) or were 98 
male (Fisher’s exact test, p=0.045). In provinces where at least 10 samples were available, there 99 
was a strong positive trend between the proportion of dogs that tested positive and the recorded 100 
burden of human disease (Spearman’s r = 0.732, p = 0.051) (Fig. 2). A similar association was 101 
observed for cats but should be viewed with caution as only four provinces met the criteria for 102 
analysis. 103 
Following its original probable transmission to humans from animals, SARS-CoV-2 has spread 104 
globally within the human population with devastating health and economic impacts. To date, 105 
SARS-CoV-2 has been sporadically detected in naturally infected dogs and cats, most of which 106 
were living in close contact with infected humans. Most studies of companion animals are small 107 
in nature, likely because of an inevitable research focus on human disease. Our results from this 108 
extensive study of SARS-CoV-2 infection in owned cats and dogs living in areas where viral 109 
transmission was active in the human population demonstrate that both cats and dogs can 110 
seroconvert under the normal conditions of pet ownership, and where the burdens of disease are 111 
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highest in humans.   112 
The link between SARS-CoV-2 household infection and a pet’s seropositivity was only apparent 113 
for dogs, possibly suggesting greater interaction between positive people and their household 114 
dogs as compared to cats. This contrasts experimental studies where dogs were less susceptible 115 
to infection (9). In addition, a higher proportion of male dogs were seropositive compared to 116 
female dogs. Future studies in animals and humans should investigate whether this phenomenon 117 
is based in physiological or behavioral differences between males and females. Although there 118 
are clear gender differences in outcomes in human COVID-19 infections, with males at higher 119 
risk of severe disease, there seems to be no evidence for a difference in infection risk (17). None 120 
of the 30 juvenile animals, less than one year-of-age, tested positive. Our findings are consistent 121 
with reports of other seropositive naturally exposed cats and dogs which were all adult (6, 7). 122 
These findings support use of older animals in experimental infections, which are currently 123 
performed on animals less than one year-of-age (9) and may therefore underestimate SARS-124 
CoV-2 susceptibility. 125 
In contrast to the serology results, all animals tested negative by PCR, including those animals 126 
living in households with confirmed COVID-19 human infection and those with and without 127 
respiratory symptoms. This suggests that whilst pet animals can seroconvert, they may shed virus 128 
for relatively short periods of time. In experimental studies, cats stopped shedding virus by 10 129 
days post infection (dpi) and developed neutralizing antibody responses by 13 dpi (9). Similar 130 
results were reported in experimental infection of dogs, in which virus was detected in faeces up 131 
to 6 dpi, but not in oropharyngeal swabs (6). However, in a naturally infected Pomeranian dog 132 
SARS-CoV-2 RNA was detected from nasal swabs by quantitative RT-PCR for at least 13 days 133 
at low titer, whilst the virus was not detected in faecal/rectal samples (7), suggesting that virus 134 
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shedding patterns may vary in some animals. Half of the challenged dogs had detectable 135 
antibodies by 14 dpi. These studies and our own highlight similar challenges in detecting SARS-136 
CoV-2 infection that exist for both humans and animals (18). It is not possible with our field data 137 
set to estimate the time of infection in animals that were seropositive, and restrictions on human 138 
and animal movement during the pandemic may have delayed visits to veterinary practitioners 139 
where sampling occurred. We advocate the inclusion of pets in ongoing assessments of 140 
community and household shedding to improve detection of active infection. 141 
In this extensive epidemiological survey of SARS-CoV-2, we found that companion animals 142 
living in areas of high human infection can become infected. Our results suggest that dogs 143 
warrant further investigation regarding SARS-CoV-2 susceptibility in contrast to experimental 144 
studies which suggested cats were most susceptible (9). We also observed seropositivity rates in 145 
animals comparable to those of humans via community sampling at a similar time in European 146 
countries (19-21). This suggests that infection in companion animals is not unusual. Based on 147 
current knowledge, it is unlikely that infected pets play an active role in SARS-CoV-2 148 
transmission to humans. However, animal-to-human transmission may be more likely under 149 
certain environmental conditions, such as the high animal population densities encountered on 150 
infected mink farms (22). As and when human transmission becomes rarer and contact tracing 151 
becomes more accessible, serological surveillance of pets may be advocated to develop a 152 
wholistic picture of community disease dynamics and ensure that all transmission opportunities 153 
are terminated. 154 
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Fig. 1. Distribution of dog and cat samples assayed for neutralizing antibody titer across Italy 265 
and the region of Lombardy. Data on human COVID-19 cases from the Italian Department of 266 
Civil Protection as of May 31, 2020 and population data from the Italian National Institute of 267 
Statistics (ISTAT), January 2019. 268 
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Fig. 2. Correlation of percentage of seropositive animals per province and human COVID-19 269 
infection density. Data points were taken from provinces with at least 10 samples. Spearman's 270 
correlation was used to assess association. 271 
Table 1. Seropositivity among dogs and cats, split into risk factor groupings where data was 272 
available. For household and sex, p value determined by Fisher’s exact test. Household COVID 273 
+ defined as one or more members of a household with a confirmed positive COVID-19 test. All 274 
the information was not available for all the animals. 275 
 276 
  Dogs     Cats      
Risk factor  No. + (total)  %   p  No. + (total)  %  p  
Household      0.004      >0.999  
   COVID+  6 (47)  12.8%    1 (22)  4.5%    
   COVID-  2 (133)  1.5%    1 (38)  2.6%    
              
Sex      0.045      0.492  
   Male  7 (83)  8.4%    2 (31)  6.5%    
   Female  2 (105)  1.9%    0 (30)  0.0%    
              
Age (years)      na      na  
   < 1  0 (20)  0.0%    0 (9)  0.0%    
   1-3  5 (70)  7.1%    1 (22)  4.5%    
   4-7  2 (83)  2.4%    1 (19)  5.3%    
   8+  4 (137)  2.9%    2 (62)  3.2%    
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   Unknown  2 (78)  2.6%    2 (39)  5.1%    
              
  277 
 278 
Materials and Methods 279 
Samples 280 
All animals were sampled by their private veterinary surgeon during a healthcare visit for other 281 
reasons. A total of 540 dogs and 277 cats were sampled from different Italian regions, mostly 282 
Lombardy (476 dogs, 187 cats). Animals were sampled either from regions severely affected by 283 
COVID-19 outbreaks in humans or from those that offered convenient access to samples. 284 
Oropharyngeal (306 dogs, 175 cats), nasal (185 dogs, 77 cats), and/or rectal (66 dogs, 30 cats) 285 
swabs were collected from the sampled pets. For 340 dogs and 188 cats, full signalment and 286 
clinical history were available, including breed, sex, age, exposure to COVID-19 infected 287 
humans (COVID-19 positive household, suspected COVID-19 positive household but not 288 
confirmed by specific assay, and COVID-19 negative household), presence of respiratory signs 289 
(cough, sneezing, conjunctivitis, nasal and/or ocular discharge).  290 
Sera were available for 188 dogs and 63 cats for which complete signalment, history and location 291 
were available (Figure 1). Additional sera were collected from diagnostic laboratories for 200 292 
dogs and 89 cats from the affected areas, but which lacked further historical information. 293 
Sampling of animals for this study was approved by the Ethics Committee of the Department of 294 
Veterinary Medicine, University of Bari, Italy (approval number 15/2020). 295 
 296 
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Polymerase chain reaction 297 
Sample preparation and RNA extraction were carried out in the biosafety level 3 containment 298 
laboratory at the Department of Veterinary Medicine, University of Bari, Italy. Detection of 299 
SARS-CoV-2 RNA used two real-time RT-PCR assays targeting nucleoprotein and envelope 300 
protein genes as previously described (11).  301 
 302 
Plaque reduction neutralization test (PRNT)  303 
The SARS-CoV-2/human/Liverpool/REMRQ0001/2020 isolate was cultured in Vero E6 cells as previously 304 
described (12). PRNTs were performed as previously described (13). Briefly, sera were heat inactivated at 56°C for 305 
1 hour and stored at -20°C until use. Dulbecco’s minimal essential medium (DMEM) containing 2% fetal bovine 306 
serum (FBS) and 0.05 mg/mL gentamicin was used for serial two-fold dilutions of serum. SARS-CoV-2 at 800 307 
PFU/mL was added to an equal volume of diluted serum and incubated at 37°C for 1 hour. The virus-serum dilution 308 
was inoculated onto Vero E6 cells, incubated at 37°C for 1 hour, and overlaid as in standard plaque assays. Cells 309 
were incubated for 48 hours at 37°C and 5% CO2 then fixed with 10% formalin and stained with 0.05% crystal 310 
violet solution. PRNT80 was determined by the highest dilution with 80% reduction in plaques compared to the 311 
control. Samples with detectable neutralizing antibody titer were repeated as technical replicates for confirmation. 312 
 313 
Data analysis 314 
Fisher’s exact test was used to analyze differences in antibody detection from households with known COVID-19 315 
infection status, and antibody detection from male and female animals. Spearman correlation was used to analyze 316 
the relationship between human COVID-19 case numbers and detection of antibodies in animals. All statistical 317 
analyses were performed in GraphPad Prism. 318 
 319 
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